Open House Originale Rabattverträge 2024-13 - Apremilast
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-13 - Apremilast
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 29, 2026
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclude Open House rebate agreements for the active substance Apremilast.
- Provide supply of pharmaceutical products under uniform contract conditions.
Show full summary
This is a German Open House pharmaceutical supply arrangement for Apremilast (CPV 33600000) led by Techniker Krankenkasse, with HEK, hkk and KKH listed as participating buyers. It is not a standard competitive award procedure: all eligible pharmaceutical companies meeting the stated conditions may join on uniform terms, with no exclusivity and no individual negotiations. The contract term runs from 01.01.2025 to 31.12.2026 at the latest, with possible earlier automatic end on patent/market exclusivity expiry. No contract value is provided in the structured data or XML. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents indicate a special deadline for 1 January 2025 inclusion.
Risks
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of German medicines law for the offered medicinal products.
- Applicant must have its seat in the AMG scope, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product(s) or otherwise be entitled to place them on the market in its own name.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2024-13 - Apremilast
Open House contract for Apremilast supply/rabatt agreements. Scope is nationwide in Germany. The lot concerns concluding uniform rebate contracts with eligible pharmaceutical companies for the active substance Apremilast. The lot information comes from structured data and XML notice.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Apremilast zu schließen.
Value note
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Apremilast zu schließen.
Procurement Details
- Publication date
- 19 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 706936-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...
Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications